IOVANCE BIOTHERAPEUTICS, INC.
About IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $263.5M
- Net income
- -$391.0M
- Total assets
- $913.2M
- Market cap
- $1.9B
- Gross margin
- -804.5%
- Operating margin
- -38735.0%
- Net margin
- -37345.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.2M
- Cost of revenue
- $10.8M
- Gross profit
- -$9.6M
- Operating expenses
- $451.0M
- Operating income
- -$460.6M
- Income tax
- -$3.5M
- Net income
- -$444.0M
- EPS (basic)
- $-1.89
- EPS (diluted)
- $-1.89
Balance sheet
- Total assets
- $780.4M
- Current assets
- $307.8M
- Total liabilities
- $195.7M
- Current liabilities
- $110.3M
- Shareholders’ equity
- $584.6M
Cash flow
- Operating cash flow
- -$361.8M
- Investing cash flow
- -$155.2M
- Financing cash flow
- $463.0M
- Net cash flow
- -$56.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-1.89
- Shares outstanding
- 472.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 26, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $391.0M in FY2025.
- Gross margin of -804.5%, net margin -37345.4%.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IOVANCE BIOTHERAPEUTICS, INC..
Write a review
News about IOVANCE BIOTHERAPEUTICS, INC.
News & sentiment via Polygon.io
